Open in interactive viewer → charts, metric popovers & call review

Kura's Launch Works; the Tape Doesn't Care

COMZIFTI up 53% sequentially and a second full-approval pathway for darlafarnib — yet KURA trades 43% below its August high as the menin class reprices
KURA · Earnings Call · 2026-11-10

A launch that is working, priced like one that isn't

Kura Oncology reported third-quarter 2026 results on November 10 with the commercial engine firing on every cylinder. COMZIFTI net product revenue reached $13.9 million, up 53% sequentially. New patient starts rose roughly 30% to about 150, total prescriptions grew 65% to more than 2,400, and the number of prescribing accounts climbed 40% to 170. Access is close to solved: coverage for nearly 100% of covered lives, with the combined Kura/Kyowa Kirin field force touching 97% of the highest-priority AML accounts. “COMZIFTI net product revenue reached $13.9 million up 53% sequentially, new patient starts increased 30%.” — Troy Edward Wilson, President and Chief Executive Officer · 2026-11-10 And the stock? KURA is down 36% over the last ninety trading days and 43% from its August 25 peak of $13.59. That gap — operating momentum one way, equity the other — is the entire story of this report. The likely culprit sits outside Kura's own numbers: competitor data released in the ASH abstracts, which management spent the first two analyst questions swatting away.

Darlafarnib, and the shape of the second act

The genuinely new thing on this call was not the menin franchise. It was the revelation that Kura has negotiated a full approval pathway for darlafarnib in HRAS-mutant salivary gland carcinoma on the basis of a single-arm study of roughly 40 patients — IND by year-end, first patient in the first half of 2027. “the FDA is aligned on a full approval for darlafarnib with a 40-patient study” — Troy Edward Wilson, President and Chief Executive Officer · 2026-11-10 That is a striking regulatory concession for a rare, HRAS-driven tumor where Mollie Leoni pegged the existing systemic response rate at about 5%. Twenty years of tipifarnib safety history plus compassionate-use data appear to be doing the confirmatory work. Strategically this is the piece investors have under-modelled. A small full approval buys premium pricing, a commercial footprint, and a regulatory precedent before the larger combination bets — darlafarnib plus cabozantinib in a randomized three-arm renal cell study (enrollment complete in 1H27), and darlafarnib plus deruxtecan in KRAS-mutant pancreatic cancer, leaning on the 67% confirmed objective response rate seen with adagrasib. Management framed it plainly as the path to being a two-commercial-product company. Whether or not one believes the 2028 KOMET-017 timeline, a KOMET 017-independent approval is a real de-risking event that did not exist in the prior narrative.

What changed: combination use stopped being the headline

On the August call, ~40% combination use was the marquee datapoint — cited repeatedly as evidence physicians were already voting for ziftomenib's combinability ahead of the label. “we have approximately 40% use in combination” — Brian T. Powl, Chief Commercial Officer · 2026-08-12 This quarter the framing shifted: combination use is now "nearly half" of patients in the claims dataset, but it is deliberately described as off-label physician discretion, with the promotional message explicitly anchored to monotherapy in the approved setting. The keyword that spiked hardest in prior quarters has quietly decayed in this one. That retreat is rational — a company that has just told you its competitive moat is combinability cannot afford to look like it is promoting beyond label — but it also removes the cleanest forward indicator bulls had. The real differentiation claim now rests on data yet to be shown. Kura goes into ASH with eight ziftomenib abstracts and four orals, including first clinical combination data with two different FLT3 inhibitors, in a population where roughly half of NPM1-mutant patients carry a concurrent FLT3 mutation.

J and J is third to market. They have gotta make some noise. ... A third of the patients are missing from the efficacy calculation. So the, you know, the efficacy evaluable is about a hundred, The, the ITT is about 146. You have to ask yourself, like, why are those patients not included?

Troy Edward Wilson, President and Chief Executive Officer · 2026-11-10
That is a CEO arguing from a defensive crouch on the tape's terms rather than his own. It may well be right — the ITT-versus-evaluable critique is a legitimate methodological point — but the market heard the noise anyway.

The two questions management would rather you didn't ask

The recurring analytical tension is duration of therapy. Kura has guided to roughly six months since launch. “Our expectation is that patients will be able to get therapy for, on average, six months.” — Brian T. Powl, Chief Commercial Officer · 2026-03-05 This quarter an analyst modelled scripts against a shorter implied duration and got a revenue number Kura did not deliver; Troy Wilson's answer was that the model was "jumping the gun" on the build curve in a relapsed/refractory population that starts sick and later-line. That is plausible. It is also the fourth consecutive call on which duration has been asserted rather than demonstrated — and the global tape is rewarding exactly this quality elsewhere, with duration of response among the better-performing oncology themes over ninety days. Kura is on the wrong side of that screen until it shows its own curves. The second evasion was transplant dynamics. Asked directly whether NPM1 patients are cycling to transplant and back to maintenance, Wilson called it "a bit of a distraction," noting single-digit-to-10% transplant rates in the trials. The underlying worry is real: any patient who leaves therapy for a transplant is a patient who stops generating prescriptions. On the mechanism question, Leoni offered the most interesting scientific colour of the call: cytopenias at competitors appear related to short half-life and twice-daily dosing, whereas ziftomenib's long half life keeps menin continuously covered — an antibiotic-style argument for why drug resistance emerges less often. It is a good story. It is not yet a proven one.

Funding solved, tape unsolved

Jennifer Fulk, on her first call as CFO, laid out $492 million of cash and short-term investments at September 30, a $32 million ATM raise at an average of about $12.67 (notably above today's price), and an OrbiMed facility of up to $300 million — $50 million drawn at close plus $5 million of equity, seven-year term, single-digit capped royalty on US COMZIFTI sales. Add roughly $180 million of anticipated Kyowa Kirin payments and the runway extends past the 2028 KOMET-017 readout. “to support our current operating plan beyond the initial Ziftomenib top line results expected in 2028” — Jennifer Fulk, Chief Financial Officer · 2026-11-10 The P&L is being managed tightly. R&D was down 2% year over year to $67 million, while SG&A fell 8% to $30.2 million and the net loss narrowed 5% to $70.2 million. But the financing has a cost: liabilities have climbed to 91.8% of assets, a structural change from a company that spent most of its life as an unencumbered cash box. Kura has traded optionality for dilution protection — sensible at $12.67, painful at $7.70.

The bottom line

Kura is executing commercially, has found a second registrational asset almost nobody was underwriting, and has funded itself past its binary event. What it has not done is win the argument about which menin inhibitor physicians will reach for in the frontline — and until the ASH combination data land, the equity will keep marking that argument as unresolved. The launch is real. The discount is a bet on the abstracts. One last thing worth noting: the CEO announced the birth of his daughter seven weeks early and confirmed he is "all in" — a human detail that, in a sector where management retention is a genuine risk factor, is doing quiet work.